CATALYST PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

24 يوليو 2024 09:55:10 بحسب NetDania Notify

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

24 يوليو 2024 08:05:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

23 يوليو 2024 10:55:07 بحسب NetDania Notify

Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

22 يوليو 2024 08:03:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

30 مايو 2024 13:41:21 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

28 مايو 2024 08:03:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

08 مايو 2024 16:16:20 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024

01 مايو 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

22 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

28 مارس 2024 08:03:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

27 مارس 2024 08:03:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

13 مارس 2024 07:55:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

05 مارس 2024 08:03:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

28 فبراير 2024 18:03:23 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

27 فبراير 2024 08:03:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

21 فبراير 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

14 فبراير 2024 08:03:00 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering

09 يناير 2024 16:05:13 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

05 يناير 2024 08:02:06 بحسب Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

04 يناير 2024 16:49:58 بحسب Nasdaq GlobeNewswire